- Home
- BOE vs QURE Comparison
BOE vs QURE Comparison
Compare BOE & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOE | QURE |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.7M | 663.4M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | BOE | QURE |
|---|---|---|
| Price | $10.64 | $14.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $44.92 |
| AVG Volume (30 Days) | 175.0K | ★ 4.6M |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | ★ 7.30% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | N/A | $210.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.16 | $7.76 |
| 52 Week High | $12.18 | $71.50 |
Technical Indicators
Market Signals| Indicator | BOE | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 26.23 | 42.74 |
| Support Level | N/A | $13.35 |
| Resistance Level | $12.04 | $15.98 |
| Average True Range (ATR) | 0.17 | 1.43 |
| MACD | -0.04 | 0.28 |
| Stochastic Oscillator | 1.62 | 12.52 |
Price Performance
Historical ComparisonAbout BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest
Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.